What does Minoryx Therapeutics BE do?

Minoryx Therapeutics BE is a research organisation in Charleroi. Public Limited, started on 28 November 2018, 1 establishment.

What is the address of Minoryx Therapeutics BE?

The registered office of Minoryx Therapeutics BE is located at Avenue Jean Mermoz 32 box 6, 6041 Charleroi.

Is Minoryx Therapeutics BE still active?

Yes. According to the CBE (29 October 2026) Minoryx Therapeutics BE is active, legal situation “Normale toestand”, started on 28 November 2018.

Is Minoryx Therapeutics BE registered on Peppol?

Yes, Minoryx Therapeutics BE is registered on the Peppol network with ID 0208:0713984534.

What is the enterprise number of Minoryx Therapeutics BE?

The enterprise number of Minoryx Therapeutics BE is BE0713984534.

When was Minoryx Therapeutics BE founded?

Minoryx Therapeutics BE was founded on 28 November 2018.

Who are the directors of Minoryx Therapeutics BE?

According to the 2025 annual accounts, the directors of Minoryx Therapeutics BE are: Minoryx Therapeutics SL, Marc Martinell Pedemonte.

Is Minoryx Therapeutics BE a reliable company?

Databakkes does not pass judgement; this is what the sources say: Active according to the CBE since 28 November 2018; 5 annual accounts filed, latest fiscal year 2025; 2 directors known from the annual account.

How much profit did Minoryx Therapeutics BE make in 2025?

Minoryx Therapeutics BE recorded a loss after taxes of € 1,087,747 in financial year 2025.

What is the revenue of Minoryx Therapeutics BE?

As a small company, Minoryx Therapeutics BE is not required to publish revenue in its annual accounts. In financial year 2025, its added value was € 242,408.

How much does an employee at Minoryx Therapeutics BE earn?

The average wage cost per full-time employee at Minoryx Therapeutics BE was € 102,600 in 2025: staff costs of € 492,244 for 4.8 FTE, according to the annual account at the National Bank. That is the employer's cost, not net pay.

How many employees does Minoryx Therapeutics BE have?

According to the 2025 annual accounts, Minoryx Therapeutics BE has 4.8 full-time equivalents (FTE).

Minoryx Therapeutics BE (Public Limited) - Charleroi

Dossier Minoryx Therapeutics BE, printed on 29 October 2026 from databakkes.be/en/0713984534/minoryx-therapeutics-be. Sources: CBE, National Bank of Belgium, Belgian Official Gazette.

Warning lights

Signals from the annual accounts, the CBE and the Official Gazette, each with its threshold and source. No score, no verdict.

Two loss years in a row NBB

Negative result in 2024 and 2025.

Financials

Financial year 2025

Minoryx Therapeutics BE from Charleroi, company number BE0713984534, closed financial year 2025 with a result of € -1.1 million after tax. For that financial year Minoryx Therapeutics BE recorded a gross margin of € 242,408 and equity of € 2.6 million. Compared with financial year 2024, the result moved from € -1.6 million to € -1.1 million. The company made a loss. The company holds a healthy buffer. A strong own buffer against the debts. The most recent annual accounts were filed with the National Bank of Belgium on July 22, 2026.

What it is worth Healthy

€ 2.6 million

▼ 42% vs 2024

Assets minus debts, by the books. What is left if everything were sold and paid today.

Loss Caution

€ -1.1 million

▲ 31 % less loss than in 2024

Profit after tax over the fiscal year.

Cash in the bank

€ 240,273

▼ 17% vs 2024

Cash and bank balances on the last day of the fiscal year.

Where the profit goes Caution

Loss, nothing to pay out

Reserves fell to € -4.1 million.

People and assets in 2025

Full-time equivalents

4.8

▼ 1 vs 2024

Average over the fiscal year, from the social balance sheet.

Wage cost

€ 492,244

▲ 1% vs 2024

€ 102,600 per full-time equivalent. Payroll staff only. What the director pays themselves is already netted into the gross margin and is not shown separately in the accounts.

Vehicles and equipment

€ 3,842

▼ 69% vs 2024

Book value of vehicles, furniture and equipment.

Debts at end 2025

Bank debt

None

No bank loans on the last day of the fiscal year.

Owed to suppliers

€ 87,379

▼ 26% vs 2024

Supplier invoices still open on the last day of the fiscal year.

Wages and social charges

€ 58,467

▼ 3% vs 2024

Wages, holiday pay and social contributions still to pay. No outstanding taxes.

Key figures per fiscal year Download key figures (CSV)
	2022	2023	2024	2025	Change 2024 → 2025
Gross margin	€ -48,697 Gross margin 2022: € -48,697 First fiscal year in the series	€ 277,198 Gross margin 2023: € 277,198 ▲ € 325,894 vs 2022 (€ -48,697) Favourable step	€ 434,325 Gross margin 2024: € 434,325 ▲ 57% vs 2023 (€ 277,198) Favourable step	€ 242,408 Gross margin 2025: € 242,408 ▼ 44% vs 2024 (€ 434,325) Unfavourable step	▼ 44%
Profit after taxes	€ -1,436,555 Profit after taxes 2022: € -1,436,555 First fiscal year in the series	€ -1,445,105 Profit after taxes 2023: € -1,445,105 ▼ € 8,550 vs 2022 (€ -1,436,555) Unfavourable step	€ -1,580,060 Profit after taxes 2024: € -1,580,060 ▼ € 134,955 vs 2023 (€ -1,445,105) Unfavourable step	€ -1,087,747 Profit after taxes 2025: € -1,087,747 ▲ € 492,313 vs 2024 (€ -1,580,060) Favourable step	▲ € 492,313
Equity	€ 4,921,357 Equity 2022: € 4,921,357 First fiscal year in the series	€ 6,993,857 Equity 2023: € 6,993,857 ▲ 42% vs 2022 (€ 4,921,357) Favourable step	€ 4,433,624 Equity 2024: € 4,433,624 ▼ 37% vs 2023 (€ 6,993,857) Unfavourable step	€ 2,553,974 Equity 2025: € 2,553,974 ▼ 42% vs 2024 (€ 4,433,624) Unfavourable step	▼ 42%
Total debts	€ 1,310,060 Total debts 2022: € 1,310,060 First fiscal year in the series	€ 883,267 Total debts 2023: € 883,267 ▼ 33% vs 2022 (€ 1,310,060) Favourable step	€ 1,203,415 Total debts 2024: € 1,203,415 ▲ 36% vs 2023 (€ 883,267) Unfavourable step	€ 1,314,199 Total debts 2025: € 1,314,199 ▲ 9% vs 2024 (€ 1,203,415) Unfavourable step	▲ 9%
Cash	€ 313,567 Cash 2022: € 313,567 First fiscal year in the series	€ 910,494 Cash 2023: € 910,494 ▲ 190% vs 2022 (€ 313,567) Favourable step	€ 290,527 Cash 2024: € 290,527 ▼ 68% vs 2023 (€ 910,494) Unfavourable step	€ 240,273 Cash 2025: € 240,273 ▼ 17% vs 2024 (€ 290,527) Unfavourable step	▼ 17%
Retained profit	€ -1,436,554 Retained profit 2022: € -1,436,554 First fiscal year in the series	€ -1,445,105 Retained profit 2023: € -1,445,105 ▼ € 8,551 vs 2022 (€ -1,436,554) Unfavourable step	€ -3,025,165 Retained profit 2024: € -3,025,165 ▼ € 1.6 million vs 2023 (€ -1,445,105) Unfavourable step	€ -4,112,911 Retained profit 2025: € -4,112,911 ▼ € 1.1 million vs 2024 (€ -3,025,165) Unfavourable step	▼ € 1.1 million
Balance sheet total	€ 6,231,418 Balance sheet total 2022: € 6,231,418 First fiscal year in the series	€ 7,877,125 Balance sheet total 2023: € 7,877,125 ▲ 26% vs 2022 (€ 6,231,418) Unchanged	€ 5,637,039 Balance sheet total 2024: € 5,637,039 ▼ 28% vs 2023 (€ 7,877,125) Unchanged	€ 3,868,172 Balance sheet total 2025: € 3,868,172 ▼ 31% vs 2024 (€ 5,637,039) Unchanged	▼ 31%
Employees (FTE)	3.8 Employees (FTE) 2022: 3.8 First fiscal year in the series	5.1 Employees (FTE) 2023: 5.1 ▲ 1.3 vs 2022 (3.8) Unchanged	5.8 Employees (FTE) 2024: 5.8 ▲ 0.7 vs 2023 (5.1) Unchanged	4.8 Employees (FTE) 2025: 4.8 ▼ 1 vs 2024 (5.8) Unchanged	▼ 1

Key figures of Minoryx Therapeutics BE, fiscal years 2022 to 2025, from the annual accounts filed with the National Bank of Belgium.Next annual account (fiscal year 2026) expected before 31 July 2027.

What happened to Minoryx Therapeutics BE?

What happened at Minoryx Therapeutics BE in recent years, according to the Belgian Official Gazette, the CBE and the National Bank:

2030 Minoryx Therapeutics SL stepped down as director. NBB
2030 Marc Martinell Pedemonte stepped down as director. NBB
Jul 22, 2026 New annual accounts for financial year 2025: loss of € 1.1 million. Source: NBB ↗
Nov 28, 2018 New establishment in Charleroi. KBO
2018 Minoryx Therapeutics SL became a director. NBB
2018 Marc Martinell Pedemonte became a director. NBB
Nov 28, 2018 Start of the company according to the CBE. KBO

In short

From € 1.4 million loss in 2022 to € 1.1 million loss in 2025.

Paid € 8 in corporate taxes since 2022.

On average € 50,500 of value added per employee in 2025.

Original PDFs at the National Bank ↗

Management

Directors

According to the 2025 annual accounts

Minoryx Therapeutics SL

Director · represented by Khalid Islam

since 2018 · until 2030

Marc Martinell Pedemonte

Director

since 2018 · until 2030

Establishments

Establishment units

Physical locations of this company

Registered office

Avenue Jean Mermoz 32 box 6

6041 Charleroi

Who else lives here?

A building full of entrepreneurs or one very busy letterbox? Another 3 companies are registered at this address.

All companies at this address →

EGEIRO PHARMA

€ 117,839 revenue · 2023

EMMA

€ -9,331 gross margin · 2025

IPRATECH

€ 1.5 million gross margin · 2025

What is an establishment unit? An establishment unit is a geographically identifiable place where activities of the enterprise are carried out.

Details

Company number

0713.984.534

VAT number

BE 0713.984.534

Registered office

Avenue Jean Mermoz 32 bus 6, 6041 Charleroi

Names & denominations

Minoryx Therapeutics BE

Enterprise type

Rechtspersoon

Legal form

Public limited company

Legal situation

Normale toestand

Start date

28 November 2018

Peppol

Active · Active since 11 Dec 2025

Activities · NACE

Overig speur- en ontwikkelingswerk op natuurwetenschappelijk gebied

Speur- en ontwikkelingswerk op biotechnologisch gebied

Overige activiteiten van vrije beroepen en andere wetenschappelijke en technische activiteiten, neg

Overige technische testen en toetsen

Vervaardiging van farmaceutische grondstoffen

Overige gespecialiseerde wetenschappelijke en technische activiteiten

View on CBE Public ↗ Annual accounts (NBB) ↗